JP2014530842A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530842A5
JP2014530842A5 JP2014536290A JP2014536290A JP2014530842A5 JP 2014530842 A5 JP2014530842 A5 JP 2014530842A5 JP 2014536290 A JP2014536290 A JP 2014536290A JP 2014536290 A JP2014536290 A JP 2014536290A JP 2014530842 A5 JP2014530842 A5 JP 2014530842A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
transthyretin
pharmaceutically acceptable
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014536290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530842A (ja
JP6068484B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/070945 external-priority patent/WO2013060668A1/en
Publication of JP2014530842A publication Critical patent/JP2014530842A/ja
Publication of JP2014530842A5 publication Critical patent/JP2014530842A5/ja
Application granted granted Critical
Publication of JP6068484B2 publication Critical patent/JP6068484B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014536290A 2011-10-24 2012-10-23 トランスサイレチン関連アミロイドーシスの新規療法 Active JP6068484B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382326 2011-10-24
EP11382326.4 2011-10-24
PCT/EP2012/070945 WO2013060668A1 (en) 2011-10-24 2012-10-23 New therapy for transthyretin-associated amyloidosis

Publications (3)

Publication Number Publication Date
JP2014530842A JP2014530842A (ja) 2014-11-20
JP2014530842A5 true JP2014530842A5 (enExample) 2015-12-10
JP6068484B2 JP6068484B2 (ja) 2017-01-25

Family

ID=47076222

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014536290A Active JP6068484B2 (ja) 2011-10-24 2012-10-23 トランスサイレチン関連アミロイドーシスの新規療法

Country Status (19)

Country Link
US (5) US9610270B2 (enExample)
EP (1) EP2770988B1 (enExample)
JP (1) JP6068484B2 (enExample)
KR (1) KR102017354B1 (enExample)
CN (1) CN103889407B (enExample)
AU (2) AU2012327275B2 (enExample)
BR (1) BR112014009322B1 (enExample)
CA (1) CA2852808C (enExample)
CL (1) CL2014000893A1 (enExample)
CY (1) CY1118151T1 (enExample)
ES (1) ES2593038T3 (enExample)
IL (1) IL231907B (enExample)
MX (2) MX347784B (enExample)
PL (1) PL2770988T3 (enExample)
PT (1) PT2770988T (enExample)
RU (2) RU2623062C2 (enExample)
SG (2) SG11201401215VA (enExample)
WO (1) WO2013060668A1 (enExample)
ZA (1) ZA201402546B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012327275B2 (en) * 2011-10-24 2017-03-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis
EP4137138A1 (en) * 2014-08-29 2023-02-22 Alnylam Pharmaceuticals, Inc. Methods of treating transthyretin (ttr) mediated amyloidosis
EP3275433A1 (en) 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
CA3093809A1 (en) * 2018-03-12 2019-09-19 Corino Therapeutics, Inc. Combination therapy for ttr amyloidosis
US20220241247A1 (en) * 2019-05-31 2022-08-04 Plex Pharmaceuticals, Inc. Pharmacological agents for treating protein aggregation diseases of the eye
MX2023005675A (es) * 2020-11-13 2023-07-31 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar afecciones del ojo.
CN114324693B (zh) * 2022-01-14 2023-01-13 大连博源医学科技有限公司 一种血液中转甲状腺素蛋白(ttr)四聚体浓度测定的预处理方法和检测方法
WO2024081554A2 (en) * 2022-10-10 2024-04-18 Corino Therapeutics, Inc. Modified release tolcapone formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
AU5727798A (en) 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
FI20002044A0 (fi) 2000-09-15 2000-09-15 Orion Yhtymae Oyj Comt-entsyymiä estäviä naftaleenijohdannaisia
PT1372682E (pt) 2001-03-15 2012-08-03 Proteotech Inc Catequinas para o tratamento de fibrilogénese em doença de alzheimer, doença de parkinson, amiloidose αa sistémica e outras perturbações amiloides
JP2006510722A (ja) 2002-01-29 2006-03-30 プロテミックス コーポレイション リミティド 細胞障害性タンパク質コンフォーマーの抑制
US20040175382A1 (en) 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CN1921856A (zh) * 2004-02-20 2007-02-28 诺瓦提斯公司 用于治疗神经变性疾病和认知障碍的dpp-iv抑制剂
JP2007523122A (ja) 2004-02-20 2007-08-16 ノバルティス アクチエンゲゼルシャフト 神経変性障害および認知障害の処置のためのdpp−iv阻害剤
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
KR101414810B1 (ko) 2004-08-30 2014-07-18 주식회사 유스팜인터내셔널 국소 허혈 모델에서의 가용화 udca의 신경보호 효과
GB2429645A (en) 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20120016037A1 (en) 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
GB0718718D0 (en) 2007-09-25 2007-11-07 Pentraxin Therapeutics Ltd Compound and use thereof
DE102010010572A1 (de) 2010-03-08 2011-09-08 Mahle International Gmbh Trockenseparator
AU2012327275B2 (en) * 2011-10-24 2017-03-02 Som Innovation Biotech, S.L. New therapy for transthyretin-associated amyloidosis

Similar Documents

Publication Publication Date Title
RU2018133158A (ru) Способы применения агонистов fxr
JP2019517587A5 (enExample)
JP2018534348A5 (enExample)
JP2009514874A5 (enExample)
JP2009530398A5 (enExample)
JP2018536641A5 (enExample)
RU2014114930A (ru) Новая терапия транстиретин-ассоциированного амилоидоза
JP2016510317A5 (enExample)
JP2014511892A5 (enExample)
JP2015511638A5 (enExample)
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
JP2007519649A5 (enExample)
RU2013121788A (ru) Ингибиторы репликации вич
JP2013542261A5 (enExample)
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
JP2006504795A5 (enExample)
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
JP2008543854A5 (enExample)
JP2008503533A5 (enExample)
JP2011505347A5 (enExample)
JP2012521355A5 (enExample)
JP2017531673A5 (enExample)
JP2015510916A5 (enExample)
RU2013113222A (ru) Способы лечения или профилактики тромбообразования или эмболии
JP2017508817A5 (enExample)